Nathaniel P. Brittingham

Array ( [id] => 8186445 [patent_doc_number] => 20120115771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-10 [patent_title] => 'CARRIER' [patent_app_type] => utility [patent_app_number] => 13/260685 [patent_app_country] => US [patent_app_date] => 2010-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 8354 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0115/20120115771.pdf [firstpage_image] =>[orig_patent_app_number] => 13260685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6296134 [patent_doc_number] => 20100240594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-23 [patent_title] => 'TARGETED DELIVERY OF CHEMOTHERAPEUTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 12/728077 [patent_app_country] => US [patent_app_date] => 2010-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10910 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0240/20100240594.pdf [firstpage_image] =>[orig_patent_app_number] => 12728077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8140737 [patent_doc_number] => 20120094919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-19 [patent_title] => 'USE OF TRIPEPTIDES' [patent_app_type] => utility [patent_app_number] => 13/254564 [patent_app_country] => US [patent_app_date] => 2010-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6502 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0094/20120094919.pdf [firstpage_image] =>[orig_patent_app_number] => 13254564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8483770 [patent_doc_number] => 20120283178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'LEARNING MOTIVATION IMPROVERS' [patent_app_type] => utility [patent_app_number] => 13/517109 [patent_app_country] => US [patent_app_date] => 2010-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3842 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13517109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9216312 [patent_doc_number] => 08629112 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-14 [patent_title] => 'Template-fixed peptidomimetics with CXCR7 modulating activity' [patent_app_type] => utility [patent_app_number] => 13/577153 [patent_app_country] => US [patent_app_date] => 2010-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10759 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13577153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7567940 [patent_doc_number] => 20110288003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'AMIDE BASED GLUCAGON AND SUPERFAMILY PEPTIDE PRODRUGS' [patent_app_type] => utility [patent_app_number] => 13/130962 [patent_app_country] => US [patent_app_date] => 2009-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 110144 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0288/20110288003.pdf [firstpage_image] =>[orig_patent_app_number] => 13130962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7511366 [patent_doc_number] => 20110257076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-20 [patent_title] => 'AMIDE BASED INSULIN PRODRUGS' [patent_app_type] => utility [patent_app_number] => 13/130966 [patent_app_country] => US [patent_app_date] => 2009-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 42833 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0257/20110257076.pdf [firstpage_image] =>[orig_patent_app_number] => 13130966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8063733 [patent_doc_number] => 20110245164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-06 [patent_title] => 'YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR' [patent_app_type] => utility [patent_app_number] => 13/130960 [patent_app_country] => US [patent_app_date] => 2009-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 51617 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0245/20110245164.pdf [firstpage_image] =>[orig_patent_app_number] => 13130960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7778898 [patent_doc_number] => 20120041174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'Counter Current Purification of Polypeptides' [patent_app_type] => utility [patent_app_number] => 13/133207 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 27399 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0041/20120041174.pdf [firstpage_image] =>[orig_patent_app_number] => 13133207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7567944 [patent_doc_number] => 20110288007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'BIOCIDAL FUSION PEPTIDE COMPRISING LL-37' [patent_app_type] => utility [patent_app_number] => 13/131817 [patent_app_country] => US [patent_app_date] => 2009-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5072 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0288/20110288007.pdf [firstpage_image] =>[orig_patent_app_number] => 13131817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7696188 [patent_doc_number] => 20110230402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'TREATING DIABETES MELITUS USING INSULIN INJECTIONS WITH LESS THAN DAILY INJECTION FREQUENCY' [patent_app_type] => utility [patent_app_number] => 13/124750 [patent_app_country] => US [patent_app_date] => 2009-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19143 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0230/20110230402.pdf [firstpage_image] =>[orig_patent_app_number] => 13124750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8749459 [patent_doc_number] => 08415292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-09 [patent_title] => 'Compositions and methods for inhibiting the interaction between CFTR and CAL' [patent_app_type] => utility [patent_app_number] => 13/124470 [patent_app_country] => US [patent_app_date] => 2009-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7591 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13124470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8465603 [patent_doc_number] => 20120270771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-25 [patent_title] => 'APOLIPOPROTEIN A-1 MIMIC PEPTIDES, AND THERAPEUTIC AGENT FOR TREATING HYPERLIPIDEMIA AND DISEASES RELATED TO HYPERLIPIDEMIA COMPRISING SAME' [patent_app_type] => utility [patent_app_number] => 13/499357 [patent_app_country] => US [patent_app_date] => 2009-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6800 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13499357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7573133 [patent_doc_number] => 20110268789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-03 [patent_title] => 'USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS' [patent_app_type] => utility [patent_app_number] => 13/120862 [patent_app_country] => US [patent_app_date] => 2009-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 24158 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0268/20110268789.pdf [firstpage_image] =>[orig_patent_app_number] => 13120862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8430851 [patent_doc_number] => 20120252727 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-04 [patent_title] => 'MUCOSAL DELIVERY OF THERAPEUTIC MOLECULES, PROTEINS, OR PARTICLES COUPLED TO CERAMIDE LIPIDS' [patent_app_type] => utility [patent_app_number] => 13/062638 [patent_app_country] => US [patent_app_date] => 2009-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 16234 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13062638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8208926 [patent_doc_number] => 20120128597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-24 [patent_title] => 'COMPOSITION FOR PREVENTION AND TREATMENT OF ALLERGIC AND/OR INFLAMMATORY DISEASES' [patent_app_type] => utility [patent_app_number] => 13/059406 [patent_app_country] => US [patent_app_date] => 2009-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6864 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0128/20120128597.pdf [firstpage_image] =>[orig_patent_app_number] => 13059406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10831561 [patent_doc_number] => 08859730 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-14 [patent_title] => 'Native chemical ligation at serine and threonine sites' [patent_app_type] => utility [patent_app_number] => 13/389202 [patent_app_country] => US [patent_app_date] => 2009-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5249 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13389202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8749460 [patent_doc_number] => 08415293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-09 [patent_title] => 'Peptide mediators of cholesterol efflux' [patent_app_type] => utility [patent_app_number] => 12/999966 [patent_app_country] => US [patent_app_date] => 2009-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 36942 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12999966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8834514 [patent_doc_number] => 08450270 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-05-28 [patent_title] => 'Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers' [patent_app_type] => utility [patent_app_number] => 12/999284 [patent_app_country] => US [patent_app_date] => 2009-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 44536 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12999284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6144504 [patent_doc_number] => 20110130346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'PEPTIDE CONJUGATES FOR DELVERY OF BIOLOGICALLY ACTIVE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 12/995380 [patent_app_country] => US [patent_app_date] => 2009-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 16729 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0130/20110130346.pdf [firstpage_image] =>[orig_patent_app_number] => 12995380 [rel_patent_id] =>[rel_patent_doc_number] =>)